Evotec stock gains on conference optimism despite weak 2026 outlook

Published on 09/19/2026 at 11:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock climbed to 3.10 EUR on Xetra on September 18, 2026, extending a rebound from a 52-week low of 2.77 EUR earlier in the week. Analysts still expect a 2026 loss per share of minus 1.297 EUR, underlining ongoing earnings pressure.

Fotorealistisches Pharma-Labor mit Wissenschaftlern bei Wirkstoffscreening in moderner Biotech-Anlage — Fotorealistisches Pharma-Labor symbolisiert Wirkstoffforschung von Evotec SE, ISIN DE0005664809, moderner Biotech-Standort Hamburg, Illustration mit AI erstellt.

Evotec stock (ISIN DE0005664809) has extended its recent rebound on Xetra, with the shares reaching about 3.10 EUR on September 18, 2026 after bouncing from a new 52-week low of 2.77 EUR earlier in the week, driven by a more optimistic tone at a recent investor conference and short covering.

Conference outlook lifts a beaten-down stock

According to Boersen-Zeitung on September 18, 2026, Evotec shares briefly touched 3.098 EUR intraday, the highest level in about a week, after management gave an optimistic outlook for the drug discovery pipeline at a conference.

As finanzen.ch reported on September 18, 2026, the stock was up 6.7 percent at 3.08 EUR around 12:28 p.m. CET, after opening the Xetra session at 2.91 EUR and marking 3.08 EUR as the intraday high.

Performance data compiled by wallstreet-online and cited on September 18, 2026 show that, despite the latest rebound, Evotec shares have fallen 47.13 percent since the beginning of 2026 and 53.05 percent over the past year.

Short interest amplifies the move

According to Aktiencheck on September 18, 2026, roughly 21.9 percent of Evotec's free float is currently sold short, creating significant potential for sharp counter-moves if sentiment improves.

The same analysis notes that the stock recently jumped about 8.5 percent from its lows, underlining how sensitive the share price has become to incremental news in a heavily shorted situation.

A separate review on September 19, 2026 by Aktiencheck points out that Evotec shares closed at 2.90 EUR in the previous session after having set a new 52-week low at 2.77 EUR earlier in the week, implying a gain of 4.7 percent between that low and the subsequent close.

Fundamentals remain under pressure

The recent price recovery is occurring against a backdrop of weak reported results. According to ad-hoc-news.de citing Evotec's mid-August release of first-half figures, revenue in the first half of 2026 fell 19.2 percent to 300.1 million EUR compared with the same period of 2025.

In the same period, adjusted EBITDA swung from minus 1.9 million EUR in the first half of 2025 to minus 42.7 million EUR in the first half of 2026, highlighting a clear deterioration in operating profitability year on year.

Per the same mid-August disclosure described by ad-hoc-news.de, Evotec confirmed its annual guidance and continues to project an adjusted EBITDA for 2026 in a negative range, a view echoed by analyses that see the company needing time to restore margins.

A more recent assessment summarized by Aktiencheck on September 19, 2026 notes that Evotec is guiding for an adjusted EBITDA in 2026 of between minus 70 million EUR and minus 105 million EUR, underscoring that management itself expects a clearly loss-making year.

In line with that outlook, consensus data for the 2026 financial year reported by finanzen.ch on September 18, 2026 point to earnings per share of minus 1.297 EUR, indicating that analysts broadly expect a net loss for the year.

Valuation and risk perspective for investors

The combination of a sharp share price decline and negative earnings expectations means that the market is effectively valuing Evotec on long-term pipeline potential rather than near-term profits, which amplifies sensitivity to news about partnerships and clinical progress.

Given the magnitude of the drawdown, with the stock sitting around 47 percent below its level at the start of 2026 and more than 50 percent below its price one year ago as of September 18, 2026 according to performance figures summarized by wallstreet-online, even modestly positive signals can trigger noticeable bounces.

At the same time, the high short interest of roughly 21.9 percent of free float reported on September 18, 2026 by Aktiencheck represents both a risk and an opportunity: further fundamental disappointments could deepen the sell-off, while convincing operational improvements could force short sellers to cover and amplify any recovery.

Evotec stock price and market data

On Xetra, Evotec stock most recently traded around 3.08 EUR intraday on September 18, 2026, up 6.7 percent from the 2.89 EUR prior close, and reached a day high of 3.08 EUR according to midday trading indications from finanzen.ch.

The same overview notes that the 52-week low of Evotec shares was set at 2.77 EUR on September 15, 2026 on Xetra, meaning the stock was trading about 11.21 percent above that low at 3.08 EUR on September 18, 2026, while longer-term performance metrics still point to pronounced weakness over recent months.